WallStreetZenWallStreetZen

NASDAQ: ATRA
Atara Biotherapeutics Inc Stock

$0.51-0.02 (-3.77%)
Updated Jun 14, 2024
ATRA Price
$0.51
Fair Value Price
N/A
Market Cap
$61.53M
52 Week Low
$0.20
52 Week High
$2.54
P/E
-0.24x
P/B
-0.63x
P/S
2.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.70M
Earnings
-$233.11M
Gross Margin
69.3%
Operating Margin
-656.95%
Profit Margin
-671.7%
Debt to Equity
-2.68
Operating Cash Flow
-$184M
Beta
1.65
Next Earnings
Aug 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ATRA Overview

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATRA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ATRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ATRA due diligence checks available for Premium users.

Be the first to know about important ATRA news, forecast changes, insider trades & much more!

ATRA News

Valuation

ATRA fair value

Fair Value of ATRA stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
-$0.72
Undervalued by
170.36%
ATRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATRA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.24x
Industry
-10.23x
Market
30.51x

ATRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.63x
Industry
6.25x

ATRA's financial health

Profit margin

Revenue
$27.4M
Net Income
-$31.8M
Profit Margin
-116.1%
ATRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATRA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$165.3M
Liabilities
$263.6M
Debt to equity
-2.68
ATRA's short-term liabilities ($180.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATRA's short-term assets ($106.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$29.6M
Investing
$14.7M
Financing
$24.1M
ATRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATRA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ATRA$61.53M-3.04%-0.24x-0.63x
LVTX$61.52M-2.50%-2.03x1.12x
CDTX$61.31M-5.08%-1.66x-3.45x
CELU$62.11M-1.38%-0.32x2.05x
DYAI$60.81M-4.59%-7.43x13.47x

Atara Biotherapeutics Stock FAQ

What is Atara Biotherapeutics's quote symbol?

(NASDAQ: ATRA) Atara Biotherapeutics trades on the NASDAQ under the ticker symbol ATRA. Atara Biotherapeutics stock quotes can also be displayed as NASDAQ: ATRA.

If you're new to stock investing, here's how to buy Atara Biotherapeutics stock.

What is the 52 week high and low for Atara Biotherapeutics (NASDAQ: ATRA)?

(NASDAQ: ATRA) Atara Biotherapeutics's 52-week high was $2.54, and its 52-week low was $0.20. It is currently -79.84% from its 52-week high and 156.78% from its 52-week low.

How much is Atara Biotherapeutics stock worth today?

(NASDAQ: ATRA) Atara Biotherapeutics currently has 120,416,138 outstanding shares. With Atara Biotherapeutics stock trading at $0.51 per share, the total value of Atara Biotherapeutics stock (market capitalization) is $61.53M.

Atara Biotherapeutics stock was originally listed at a price of $10.65 in Oct 16, 2014. If you had invested in Atara Biotherapeutics stock at $10.65, your return over the last 9 years would have been -95.2%, for an annualized return of -28.64% (not including any dividends or dividend reinvestments).

How much is Atara Biotherapeutics's stock price per share?

(NASDAQ: ATRA) Atara Biotherapeutics stock price per share is $0.51 today (as of Jun 14, 2024).

What is Atara Biotherapeutics's Market Cap?

(NASDAQ: ATRA) Atara Biotherapeutics's market cap is $61.53M, as of Jun 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Atara Biotherapeutics's market cap is calculated by multiplying ATRA's current stock price of $0.51 by ATRA's total outstanding shares of 120,416,138.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.